0000950170-24-035517.txt : 20240322 0000950170-24-035517.hdr.sgml : 20240322 20240322174506 ACCESSION NUMBER: 0000950170-24-035517 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240320 FILED AS OF DATE: 20240322 DATE AS OF CHANGE: 20240322 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KASINGER JAMES R. CENTRAL INDEX KEY: 0001708172 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 24776427 MAIL ADDRESS: STREET 1: C/O CRISPR THERAPEUTICS, INC. STREET 2: 610 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 4 1 ownership.xml 4 X0508 4 2024-03-20 0001674416 CRISPR Therapeutics AG CRSP 0001708172 KASINGER JAMES R. C/O CRISPR THERAPEUTICS 105 WEST FIRST STREET BOSTON MA 02127 false true false false General Counsel and Secretary false Stock Option (Right to Buy) 72.94 2024-03-20 4 A false 33333 0 A 2034-03-20 Common Shares 33333 33333 D Restricted Stock Units 2024-03-20 4 A false 25000 0 A Common Shares 25000 25000 D This option was granted on March 20, 2024 with respect to 33,333 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2024. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. /s/ AJ Silver, attorney-in-fact 2024-03-22